# OnCo record insilico-medicine (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/insilico-medicine/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "insilico-medicine" ;
  schema:name "Insilico Medicine"@en ;
  schema:description "Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic."@en ;
  schema:url <https://onco.cc/companies/insilico-medicine/>, <https://insilico.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Insilico_Medicine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q43080151> ;
  schema:citation <https://www.biospace.com/press-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026> ;
  schema:addressCountry "HK" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:sections <https://onco.cc/fronts/ai-computation/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:trials <https://onco.cc/trials/nct06414460/>, <https://onco.cc/trials/nct06566079/> .